Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight ...
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average ... a patient's heart health through methods beyond weight loss, the study authors concluded. Notably, the weight loss ...
That could boost Novo Nordisk's case for insurers and governments to cover the costly but effective drug. Participants were not required to track diet and exercise because it was not an obesity study.
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...